- Home
- DNLI vs TMDX Comparison
DNLI vs TMDX Comparison
Compare DNLI & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DNLI | TMDX |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.8B |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DNLI | TMDX |
|---|---|---|
| Price | $20.04 | $100.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 9 |
| Target Price | $34.33 | ★ $148.22 |
| AVG Volume (30 Days) | ★ 1.2M | 763.2K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | N/A | ★ 4.87 |
| Revenue | N/A | ★ $605,494,000.00 |
| Revenue This Year | N/A | $24.25 |
| Revenue Next Year | $408.85 | $18.75 |
| P/E Ratio | ★ N/A | $22.26 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $12.58 | $88.51 |
| 52 Week High | $23.77 | $156.00 |
Technical Indicators
Market Signals| Indicator | DNLI | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 49.30 | 37.47 |
| Support Level | $18.86 | $97.66 |
| Resistance Level | $20.71 | $120.60 |
| Average True Range (ATR) | 0.85 | 5.39 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 35.74 | 1.91 |
Price Performance
Historical ComparisonAbout DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.